Wegovy shows early momentum with 3,071 U.S. prescriptions in launch days
TL;DR Summary
Novo Nordisk’s oral Wegovy drew 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts show, indicating early momentum in a competitive weight‑loss market as the company vies with Eli Lilly. The figure counts retail prescriptions only (not online NovoCare Pharmacy fillings), so actual demand is likely higher.
- Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch Reuters
- Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch CNBC
- Lubbock Doctor compares weight loss injections to new pills KCBD
- Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus Yahoo Finance
- Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030 Reuters
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
28 min
vs 29 min read
Condensed
99%
5,694 → 54 words
Want the full story? Read the original article
Read on Reuters